medigraphic.com

2000, Número 2

<< Anterior Siguiente >>

Enf Infec Microbiol 2000; 20 (2)


Nuevas tendencias en el manejo del paciente: tratamiento basado en el riesgo para pacientes febriles con neutropenia
Fiebre y neutropenia: cómo usar una nueva estrategia de tratamiento
Estudio comparativo doble ciego de tratamiento antibiótico empírico oral e intravenoso para pacientes febriles de bajo riesgo con neutropenia que están recibiendo quimioterapia para cáncer
Tratamiento antimicrobiano empírico oral vs intravenoso para fiebre en pacientes con granulocitopenia que están recibiendo quimioterapia para cáncer
La vancomicina como parte del tratamiento antibiótico empírico inicial para neutropenia febril en pacientes con cáncer: pros y contras

Rolston KVI, Finberg RW, Talcott JA, Freifeld A, Marchigiani D, Wals T, Kern WV, Cometta A, de Bock R, Feld R

Idioma: Español
Referencias bibliográficas: 22
Paginas: 61-80
Archivo PDF: 98.79 Kb.


FRAGMENTO

El manejo estándar de la neutropenia febril incluye la administración oportuna de tratamiento empírico con antibióticos parenterales de amplio espectro.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: An increased cause of infection in patientswith granulocytopenia. Ann Intern Med 1982;96:503-8.

  2. EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteremia in granulocytopenic cancer patients. Eur J Cancer 1990;26:569-74.

  3. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.

  4. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.

  5. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine 1984;63:189-200.

  6. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram-positive bacteremia and the impact of empirical administration of vancomycin. Eur J Cancer 1996;32A:1332-9.

  7. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.

  8. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and Streptococcus bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin vs a placebo combined with pefloxacin. JAMA 1994;272: 1183-9.

  9. Bow EJ, Mandel LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996;125:183-90.

  10. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-35.

  11. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053-8.

  12. EORTC International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.

  13. Ramphal R, Bolger M, Obion DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study. Antimicrob Agents Chemother 1992;36:1062-7.

  14. Pico JL, Marie JP, Chiche D, et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med 1993;2:275-80.

  15. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.

  16. De Pauw BE, Deresinski SC, Feld R, Lane-Aliman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial. Ann Intern Med 1994;120:834-44.

  17. Wade JJ. Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997;16:113-9.

  18. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.

  19. Suppola JP, Volin L, Valtonen VV, Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996;23:694-7.

  20. Henning KJ, Delencastre H, Eagan J, et al. Vancomycinresistant Enterococcus faecium on a pediatric oncology ward: Duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:845-7.

  21. Philpott NJ, Brownlee R, Morrison D, et al. Vancomycinresistant enterococci (VRE) on a leukemia/BMT unit [abstract no. 0335]. Bone Marrow Transplant 1997;19(suppl 1):S84.

  22. Recommendations for preventing the spread of vancomycin resistance Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1994;44:1-13.




2020     |     www.medigraphic.com